Home
About
FAQ
History (13)
Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis.
Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs.
Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
Prevalence and Correlates of Uncontrolled Hypertension, Persistently Uncontrolled Hypertension, and Hypertensive Crisis at a Healthcare System.
Costs of Common Psoriasis Medications, 2010-2014.
See All 13 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Costs of Common Psoriasis Medications, 2010-2014.
James SM, Hill DE, Feldman SR. Costs of Common Psoriasis Medications, 2010-2014. J Drugs Dermatol. 2016 Mar; 15(3):305-8.
View in:
PubMed
subject areas
Administration, Topical
Biological Products
Cost-Benefit Analysis
Dermatologic Agents
Glucocorticoids
Humans
Prescription Fees
Psoriasis
authors with profiles
Steven R. Feldman MD, PhD